A new study published The Lancet journal finds that excess cardiovascular and mortality risk varies with age at diagnosis of type 1 diabetes (T1D).
“Attention has focused appropriately on modifiable cardiovascular disease risk factors such as glucose control, blood pressure, and cholesterol. However, non-modifiable cardiovascular disease risk factors, age at the time of the diagnosis being an example, might also help direct timing of therapy for modifiable risk factors,”
- During a median follow-up of 10 years, 959 individuals with T1D and 1,501 controls died.
- Among patients who developed T1D at 0 to 10 years of age, the hazard ratios were significantly increased for all-cause mortality (4.11), cardiovascular mortality (7.38), non-cardiovascular mortality (3.96), cardiovascular disease (11.44), coronary heart disease (30.50), acute myocardial infarction (30.95), stroke (6.45), and heart failure (12.90), and non-significantly increased for atrial fibrillation (1.17).
- For patients who developed diabetes at age 26 to 30 years, the hazard ratios were also significantly increased for all-cause mortality (2.83), cardiovascular mortality (3.64), non-cardiovascular mortality (2.78), cardiovascular disease (3.85), coronary heart disease (6.08), acute myocardial infarction (5.77), stroke (3.22), and heart failure (5.07), and non-significantly increased for atrial fibrillation (1.18).
- Across different diagnosis age groups, the excess risk differed by up to five times.
“Age at onset of T1D is an important determinant of survival, as well as all cardiovascular outcomes, with highest excess risk in women. Greater focus on cardioprotection might be warranted in people with early-onset T1D,” conclude the authors.
For further reference log on to https://doi.org/10.1016/S0140-6736(18)31506-X
Latest posts by Medha Baranwal (see all)
- Drug combo effective in Penile fibrosis, preventing impotence - November 14, 2018
- Sacubitril–valsartan therapy -New standard care for acute heart failure - November 14, 2018
- Triple-Drug Therapy more effective in lymphatic filariasis: NEJM - November 13, 2018